The PDF File that goes along with the Rucaparib for Covid Preprint posted below on Page 3 of this PDF File says the following about Rucaparib. HUGE

These findings build a case for repurposing rucaparib for treating COVID-19 disease.

GET THIS OUT EVERYWHERE.

Rubraca best. Pfizer new PARP terrible.

https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fbreastsclinic.com%2Fthe-drug-discoverer-understanding-the-off-target-effects-of-cancer-drugs-and-how-they-could-lead-us-to-new-forms-of-treatment%2F15185%2F%3Famp%3D1&data=05%7C01%7C%7C16fd48767d1e408563c708da5c52e6b2%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C637923808381542123%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=iaL2lrDWGPHNb2OSuoP7M8J1o8GoArUCmOg%2FSA8FndY%3D&reserved=0

Rubraca blocks COVID from attaching to cells


https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.1101%2F2022.06.30.22277079v1&data=05%7C01%7C%7Cd3de362343a84919e0d608da5c51135e%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C637923800526080926%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=5xoSWS9Icay5I5VGOJppwL970ZrUUGDuQ3WhV%2BVceA0%3D&reserved=0

Oil futures over $125 a barrel. Do we still have leases that could be drilled???

Congratulations if you held on thru a tough ride. Unfortunately I didn't but my bad.

Another Buyout rumor starting. This time Sanofi.

Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program

https://newsfilter.io/articles/clovis-oncology-announces-presentations-at-2020-asco-virtual-scientific-program-c809f22aa75866c6e72796ff7b89b3c8

Sure seems to me a ratio of 9/10 longer PFS for those with the RAD51 Mutation could be a big deal. Just looking that up I see it's mostly associated with breast cancer. Any thoughts?

$CLVS "Among patients with a tumor associated with a RAD51C/D mutation, there was significantly longer PFS in those receiving rucaparib than in those receiving placebo (log rank P value, 0.0184); 9/10 rucaparib versus 0/3 placebo patients were progression-free at 12 months. "

https://sgo.confex.com/sgo/2020/meetingapp.cgi/Paper/15078

Fingers crossed

Meeting Library | Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with <em>BRCA1</em> or <em>BRCA2 </em>(<em>BRCA</em>)<em>-</em>mutated metastatic castration-resistant prostate cancer (mCRPC).

https://meetinglibrary.asco.org/record/183581/abstract

Only thing I've seen but someone may have seen Pat's charts for Monday. I really believe he will be looking to close a Buyout deal at the conference.

Will Clovis’ Rubraca sales shortfall revive talk of a buyout at JP Morgan? | FiercePharma

https://www.fiercepharma.com/pharma/will-clovis-s-rubraca-sales-shortfall-revive-talk-a-buyout-at-jp-morgan

When is the Escrow available? That's when I expect something will happen.

BMY announced the purchase of Celgene on Jan 3rd last year. Makes a lot of sense.

Clovis: Evaluating The Prospect Of The BMS Acquisition | Seeking Alpha. $5.1B

https://seekingalpha.com/instablog/17806842-biosci-capital-partners/5387581-clovis-evaluating-prospect-of-bms-acquisition

FAP-2286 possibilities are exciting. Research Dr Richard Baum.


http://www.1stoncology.com/blog/initial-clinical-experience-reported-from-fap-2286-named-patient-use-at-icpo-symposium1234552394/

Doesn't look like it. More like $20 soon.

That was my question exactly. We have enough cash to fund us till 2021. I was well aware the convertibles would convert to shares so expected. Less debt.

So will you address my question please? Here is more on yours.

Obviously we already have Rubraca which is growing internationally. Then we have the prostrate updated filing due before year-end. And...

Rubraca and sacituzumab combo inmTNBC, advanced urothelial cancer (UC) and second-line metastatic NSCLC. Preliminary readout of Clovis and IMMU collaboration may be presented at SABCS in few days.

Possibly next week.

So the net result of all this will be an increase in shares (expected) reflected in the 10K but also a decrease to debt. Correct? If the shares were loaned then at some point they must buy them back? My avg price is about $4 and I'm hoping for excellent trial results so not going anywhere.

Somebody knows something. Big players buying.

Go CLVS

These 3 Value Stocks Are Absurdly Cheap Right Now | The Motley Fool

https://www.fool.com/investing/2019/11/22/these-3-value-stocks-are-absurdly-cheap-right-now.aspx

best wishes to you Myth

you didnt underline the statement "if this will occur" speaking of a distribution. So after committing to a distribution for two years now its not definite that there will be one at all.

ive calmed down but still angry at Davids condescending attitude toward owners/shareholders.

i may be wrong but i believe all our company board members are employees of Red Oak. will research everything this coming week before sending my complaint. angers me that twice he has committed to pay shareholders a dividend & twice he has failed to deliver while giving nebulous excuses.

ive decided to file a complaint with the SEC. I believe david has a conflict between what is best for shareholders & his hedge fund. i also believe he has misled shareholders on distribution of funds using the last minute gimmick of potential non-taxable payouts which has since disappeared from the discussion. finally he has kept shareholders completely in the dark about how he is investing our cash. and i believe he is paying at least one employee of his hf a salary out of our funds.

pretty sure some of you have other thoughts. please post as i plan to file sometime next week. others should also but that is your decision. i can assure you my complaint will be thorough & professional when submitted.

dont know what is going on but im really not happy with our CEO David Sandberg. he has treated us shareholders like low level employees instead of owners. and i let him know it. i sold much of my position because the price growth to .011 wasnt enough to keep me interested. but i still have over a million shares.

here is the new wording filed tonight updating his prior statement. says nothing as usual. yes im angry.

CBAI previously disclosed that it anticipated distributing a portion of the sale proceeds to shareholders in 2019. With the goal of maximizing shareholder value, CBAI and its board of directors are also evaluating other alternatives including potentially pursuing a plan of liquidation and dissolution and/or a sale of the Company. In order to enable any such alternatives to be fully explored, the Company may not distribute a portion of the sale proceeds to its shareholders in 2019. The Company has no commitments, agreements or understandings with respect to any such alternatives and there can be no assurance that any such alternatives will be consummated or the terms thereof. CBAI and its Board of Directors continue to contemplate a distribution, but based on discussions, evaluations, and business judgement, have not yet determined if this will occur, or when. Regardless of the alternative(s) undertaken by the Company given the Company’s expenses and other contingencies the total proceeds ultimately paid out to shareholders will be significantly less than the gross purchase price the Company received from its Purchase Agreement with FamilyCord.

I'm back out. Too many issues.

Consensus estimate for 3Q is $376.2M of Revenue & a loss of (,62) per share. We did $373.7M last quarter & I expect the growth to be more.

I'm back in. Hopefully an upbeat report tomorrow. Also hoping analyst will be a little less harsh on the new management team.

Any thoughts on the upcoming 3Q numbers? I've been out of Overstock but am thinking about jumping back in Monday ahead of earnings on Tuesday.

Check out the Seeking Alpha article that came out on Nov 6th and read the comment from ConservativeTea at the bottom. She is convinced Rubraca cured her cancer.


https://seekingalpha.com/article/4303398-clovis-oncology-classic-story-value-disconnect

New filing. Perhaps a prelude to a deal.

Higher share price actually enhances Buyout possibilities. Clovis would never sell for less than $30.

Hope so

Yep. Very positive Earnings Report. This is still a bargain at these prices.